Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis
This phase II trial studies the long-term side effects of ruxolitinib in treating patients with myelofibrosis. Collecting data about the long-term safety and tolerability of ruxolitinib may better help future patients with myelofibrosis.
|Condition or Disease||Intervention/Treatment||Phase|
- To collect long term safety and tolerability data in patients with myelofibrosis previously treated with ruxolitinib on protocol 2007-0169.
Patients continue to receive ruxolitinib orally (PO) once daily (QD) or twice daily (BID). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo follow-up assessment for safety over 10 minutes every 3 cycles.
Arms and Interventions
|Experimental: Treatment (ruxolitinib, follow-up)
Patients continue to receive ruxolitinib PO QD or BID. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo follow-up assessment for safety over 10 minutes every 3 cycles.
Other: Long-term Follow-up
Undergo follow-up assessment
Other: Quality-of-Life Assessment
Primary Outcome Measures
- Incidence of adverse events [Up to 3 years]
Safety data of the patients will be summarized using descriptive statistics such as mean, standard deviation, median and range. Will follow standard reporting guidelines for adverse events. Safety data will be summarized by category, severity and frequency.
Currently enrolled in study 2007-0169 and benefiting from therapy as determined by treating physician
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 at enrollment of this study
Ability and agreement to attend protocol-specified visits at the study site
Able to comprehend and willing to sign the informed consent form
Negative pregnancy test in females of childbearing potential; male patients with female partners of child-bearing potential and female patients of childbearing potential are required to use two forms of acceptable contraception, including one barrier method, during their participation in the study and for 30 days following last dose; acceptable forms of contraception include 1 highly effective method such as an intrauterine device (IUD), hormonal (birth control pills, injections, or implants), tubal ligation, or partner's vasectomy and at least 1 additional approved barrier method such as a latex condom, diaphragm, or cervical cap; female patients of childbearing potential must not be breast-feeding or planning to breast feed and must have a negative pregnancy test 7 days before first study treatment
Contacts and Locations
|1||M D Anderson Cancer Center||Houston||Texas||United States||77030|
Sponsors and Collaborators
- M.D. Anderson Cancer Center
- National Cancer Institute (NCI)
- Principal Investigator: Prithviraj Bose, M.D. Anderson Cancer Center
Study Documents (Full-Text)None provided.